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Abstract
Background: Probiotics purportedly reduce symptoms of gastrointestinal and upper respiratory-tract illness by
modulating commensal microflora. Preventing and reducing symptoms of respiratory and gastrointestinal illness
are the primary reason that dietary supplementation with probiotics are becoming increasingly popular with
healthy active individuals. There is a paucity of data regarding the effectiveness of probiotics in this cohort. The
aim of this study was to evaluate the effectiveness of a probiotic on faecal microbiology, self-reported illness
symptoms and immunity in healthy well trained individuals.
Methods: Competitive cyclists (64 males and 35 females; age 35 ± 9 and 36 ± 9 y, VO2max 56 ± 6 and 52 ± 6 ml.
kg-1.min-1, mean ± SD) were randomised to either probiotic (minimum 1 × 109 Lactobacillus fermentum (PCC®) per
day) or placebo treatment for 11 weeks in a double-blind, randomised, controlled trial. The outcome measures
were faecal L. fermentum counts, self-reported symptoms of illness and serum cytokines.
Results: Lactobacillus numbers increased 7.7-fold (90% confidence limits 2.1- to 28-fold) more in males on the
probiotic, while there was an unclear 2.2-fold (0.2- to 18-fold) increase in females taking the probiotic. The
number and duration of mild gastrointestinal symptoms were ~2-fold greater in the probiotic group. However,
there was a substantial 0.7 (0.2 to 1.2) of a scale step reduction in the severity of gastrointestinal illness at the
mean training load in males, which became more pronounced as training load increased. The load
(duration×severity) of lower respiratory illness symptoms was less by a factor of 0.31 (99%CI; 0.07 to 0.96) in
males taking the probiotic compared with placebo but increased by a factor of 2.2 (0.41 to 27) in females.
Differences in use of cold and flu medication mirrored these symptoms. The observed effects on URTI had too
much uncertainty for a decisive outcome. There were clear reductions in the magnitude of acute exercise-
induced changes in some cytokines.
Conclusion: L. fermentum may be a useful nutritional adjunct for healthy exercising males. However, uncertainty in
the effects of supplementation on URTI and on symptoms in females needs to be resolved.
Trial registration: The trial was registered in the Australia and New Zealand Clinical Trials Registry
(ACTRN12611000006943).
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Background
Probiotics are becoming increasingly popular as a nutri-
tion supplement to reduce susceptibility to common
infectious illnesses, particularly upper respiratory tract
(URT) and gastrointestinal (GI) illness. For athletes,
reducing the occurrence of these illnesses is a high
priority. There is a heightened incidence of URT and GI
illness, particularly diarrhoea, during heavy training and
competitions [1-3]. The increased susceptibility to illness
is thought to relate to acute post-exercise immune per-
turbations and chronic suppression of immune factors
due to frequent heavy exercise [4,5]. These perturba-
tions in immunity are proposed to provide a window of
opportunity for micro-organisms to establish infection.
Illness during heavy training or competition may have
negative consequences for athletic performance [6]. As
such, probiotics, may offer a nutrition strategy to limit
illness affecting performance.
There is increasing evidence that probiotic supple-
mentation, alone or in combination with other preventa-
tive agents such as prebiotics, can reduce the number,
duration and severity of acute infectious diarrhoea and
URTI in the general population [7-9] and in at risk sub-
groups, such as the elderly [10]. This evidence has led
to interest in the use of probiotics to reduce illness in
athletes. Moderating or ameliorating acute and chronic
exercise-induced perturbations in immunity via the use
of probiotic supplementation may be one strategy of
reducing susceptibility to illness. Initial research examin-
ing the efficacy of probiotics in physically active groups
has thus far been inconclusive. Three studies indicated
that probiotic supplementation might be useful for
enhancing immunity and reducing the duration of URTI
and GI illness in endurance-based athletes [11-13],
whereas probiotic supplementation by commando cadets
during a training and combat course had little effect on
the incidence of URTI [14]. These findings are not sur-
prising given sample size, length of the supplementation
and illness observation period and differences in probio-
tic strain and dosage [15]. Despite the mixed findings
from scientific research, however, probiotics are increas-
ing in popularity in healthy active groups, mirroring the
trend generally in developed countries [16]. Given the
inconsistent findings of efficacy between physically
active groups and the growing popularity of probiotic
supplements, it is necessary that the benefits of supple-
mentation are substantiated to ensure individuals make
informed choices.
Concerns on the safety and efficacy of probiotics have
recently led to calls for the development of interpretive
frameworks on the ratio of clinical benefit to risk [17].
In most published probiotic studies (and other dietary
supplements) knowledge of the risks has not been
considered when characterising the potential benefits of
use. Analytical approaches that specify clinically impor-
tant thresholds of effect, either positive or negative [18],
rather than only statistically significance, offer better
clinical insights for making decisions regarding the use
of probiotics as a supplement.
The primary aim of this study was to determine the
effects of supplementation with Lactobacillus fermentum
(PCC®) on URTI and GI symptoms in a cohort of
healthy, physically active individuals over a 15-week
winter training period. A secondary aim was to establish
the effect of supplementation with L. fermentum (PCC®)
on faecal microbiology and key aspects of immunity at
rest and in response to an exercise test to exhaustion.
Methods and Subjects
Study design
The study involved a randomised, double-blind, placebo-
controlled parallel-groups design consisting of an initial
2-wk pre-supplement (baseline) period, 11.0 ± 0.4 wk
(mean ± SD) of supplementation and a 2-wk post-sup-
plement follow-up period. Subjects were recruited and
randomly allocated using a computer generated list to
either probiotic or placebo treatment based on gender,
age and maximal oxygen uptake (VO2max) by a
researcher independent from the study team. Partici-
pants and the study team were blinded to the interven-
tions until the completion of the statistical analysis as
the probiotic and placebo were manufactured to be
identical in packaging, encapsulation and taste.
Cyclists and triathletes from Canberra, Australia and
its surrounding regions were contacted via email alerts
and during competition to participate in the study by
the main researcher. One hundred and nine cyclists
volunteered. Subjects were required to declare their use
of other dietary and/or ergogenic aids that may have
influenced underlying immune function and/or exercise
performance. All subjects on immuno-modulatory medi-
cations were excluded. Inclusion in the study was
dependent on the subjects not taking antibiotics or sup-
plements/foods containing probiotics for at least one
month prior to and during the study period. Subjects
were also required to have a maximal oxygen uptake
(VO2max) of at least 45 ml/kg/min for women and 50
ml/kg/min for men. Ninety-nine subjects met the study
requirements.
Subjects consumed one capsule daily of either the pro-
biotic or placebo supplement. The probiotic capsule
contained a minimum of one billion (109) colony-form-
ing units of Lactobacillus fermentum VRI-003 PCC®
(Probiomics Ltd, Sydney, Australia). This dose was cho-
sen on the basis of commercial viability and is consis-
tent with other probiotic studies showing efficacy for
West et al. Nutrition Journal 2011, 10:30
http://www.nutritionj.com/content/10/1/30
Page 2 of 11
URTI and GI illness [19]. The placebo supplement con-
sisted of microcrystalline cellulose. Subjects were able to
consume the supplement at any time with or without
food. Subjects returned the bottles following supplemen-
tation and capsules were counted to verify the degree of
compliance. All subjects completed a four day food
diary during the study that incorporated two week days
and a weekend to allow adjustment for the effect of
dietary food intake on microflora. Verbal and written
guidelines were provided to subjects to ensure foods
were recorded accurately. Detailed descriptions includ-
ing brand name, packaging, method of preparation and
quantity were recorded. Subjects were asked to maintain
a normal diet beyond the instruction to refrain from
eating probiotic-enriched yoghurt and probiotic or pre-
biotic enriched foods or supplements. All records were
reviewed by a dietician. Total energy (kJ), carbohydrate
(g), fat (g), protein (g) and fibre (g) were assessed by
using FoodWorks professional edition software package
(version 3.0, Xyris Software, Brisbane, Australia).
This study was conducted according to the guidelines
of the Declaration of Helsinki and all procedures invol-
ving human subjects were approved by the Human
Research Ethics Committees of the Australian Institute
of Sport and Griffith University. All participants pro-
vided written informed consent.
Illness symptoms
Subjects recorded symptoms of GI, URT and lower
respiratory illness on a daily illness log over the study
period, as previously described [20]. Briefly, symptoms
of GI illness included nausea, vomiting, diarrhoea,
abdominal pain, abdominal bloating, flatulence, stomach
“rumbles” and loss of appetite. URTI symptoms
included throat soreness, sneezing, a blocked or runny
nose and cough. Lower respiratory illness symptoms
included coughing with chest congestion and/or wheez-
ing. Two or more symptoms on at least two consecutive
days were defined during the analysis as an episode of
illness. Symptoms separated by only one day were
counted as the same episode. The severity of symptoms
were self-rated as mild, moderate or severe based on the
impact of the symptoms on training for that day, with
mild symptoms resulting in no change to training, mod-
erate symptoms necessitating a reduction in training
volume and/or intensity, and severe symptoms leading
to a total cessation of training on that day[20]. The
duration and mean severity of each episode were calcu-
lated. Subjects were also asked to record all medications
consumed during the study, including antibiotics, anti-
inflammatories, pain killers, decongestants and anti-his-
tamines. Dietary supplements that might have influ-
enced underlying immune function or exercise
performance were also recorded.
Training and performance measures
Subjects recorded information on all types of physical
activity undertaken during the study. For each training
session subjects recorded training distance (km), dura-
tion (min) and intensity (scored on a 1-5 scale: 1, easy;
5, maximal). At the start and end of the study subjects
undertook an incremental performance test to deter-
mine peak power output, VO2max and the acute post-
exercise cytokine response. The test was performed on a
cycle ergometer (Excalibur Sport, Lode NV Groningen,
the Netherlands) as previously described [21].
Sample collection
Saliva and blood samples from all subjects, and faecal
samples from a cohort of 20 subjects from each group
(10 male and 10 female), were obtained pre- and post-
supplementation. Saliva was collected using an eye spear
(Defries Industries, Victoria, Australia). The eye spear
was placed between the cheek and teeth for up to five
minutes, centrifuged for 5 minutes at ~800 g and frozen
at -80°C until analysis. Albumin concentration and
osmolality was assessed to control for changes in sali-
vary flow rate and hydration. All saliva samples were
taken at the same time of the day to control for diurnal
variation. Blood samples were taken prior to and imme-
diately after the acute exercise challenge undertaken at
the start and end of supplementation. Pre-exercise post-
prandial samples were used to determine whether sup-
plementation enhanced resting plasma cytokine concen-
trations. Blood samples taken immediately after the
exercise challenge were used to determine if supplemen-
tation ameliorated the acute post-exercise plasma cyto-
kine response. Blood samples were drawn directly into
K3EDTA tubes (Greiner Bio-one; Frickenhausen, Ger-
many) from an antecubital vein immediately before and
after the exercise test to exhaustion. Plasma was sepa-
rated by centrifugation at ~800 g for 5 min and stored
frozen at -80°C until analysis. Faecal samples were col-
lected in a sealable plastic bag and frozen immediately
in a portable -20°C freezer (Waeco Pacific Pty Ltd).
Measures of mucosal immunity
Lactoferrin, lysozyme and SIgA concentrations were
measured spectrophotometrically by enzyme linked
immunosorbant assay (ELISA) using commercial kits
(lactoferrin - EMD Chemicals, New Jersey, USA, lyso-
zyme - Sapphire Bioscience Redfern Australia, SIgA -
Salimetrics, IgA -Salimetrics, Philadelphia, USA).
Albumin concentration was measured by immunotur-
bidimetric assay on a Hitachi 911 Chemistry Analyser
(Roche). Osmolality was measured on a Model 3320
Osmometer (Advanced Instruments Inc) as per the
manufacturer’s instructions. The inter-assay variability
for high and low controls in the lactoferrin, lysozyme
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and SIgA assays are included in Table three. Variability
was acceptable at < 10% for the low and high positive
controls.
Measures of systemic immunity
The cytokines analysed were granulocyte macrophage-
colony stimulating factor, (GM-CSF), interleukin (IL)-
1RA, IL-6, IL-8, IL-10, tumor necrosis factor (TNF)-a
and interferon gamma (INF-g). The concentration of
plasma cytokines were measured on a Bio-Plex Suspen-
sion Array System (Bio-Rad Laboratories Pty Ltd; Her-
cules, CA, USA). The samples were analysed on custom
manufactured Multiplex Cytokine Kits (Bio-Rad Labora-
tories Pty Ltd; Hercules, CA, USA). Plates were read
using the Bio-Plex Suspension Array System (Bio-Rad
Laboratories Pty Ltd; Hercules, CA, USA). A full blood
count including white cell count and differential were
analysed on a haematology analyser (Advia, GMI, MI,
USA). Results from each assay were accepted if the posi-
tive controls were within two standard deviations from
their established mean concentration. The CVs for the
low and high controls ranged from 4.5% to 12%.
Molecular microbiology
DNA was extracted according to Abell et al. [22] and
quantified using Quant-iT™ Picogreen (Invitrogen).
Microbiome diversity was examined using a universal
bacteria 16S rRNA primer set (907f - 1392rgc). The
amplified product was analysed by denaturing gradient
gel electrophoresis (DGGE). The PCR and DGGE gel
conditions followed the protocol of Abell et al. [22] with
the exception that a 35% - 70% denaturing gradient was
used. Dominant DGGE bands were extracted from the
gels and sequenced for putative identification. DNA was
extracted from the DGGE bands using a modification of
the method described by Boom et al. [23]. The DGGE
bands were excised from the gels using a x-tracta
(Geneworks, Hindmarsh, SA, AU) and transferred to a
1.7 ml tube and submerged in 100 μl of diffusion buffer
(0.5M ammonium acetate; 10 mM magnesium acetate; 1
mM EDTA pH 8.0; 0.1% SDS) followed by incubation at
50°C for 30 min. The extracted DNA was then re-ampli-
fied using the primers 907f and 1392r without the GC-
clamp and sequenced in both directions by capillary
separation on an AB 3730xl sequencer. The sequences
were then quality checked and assembled using the soft-
ware packed ChromasPro version 1.41 (Technelysium
Pty Ltd). The complete sequences were then putatively
identified using Basic Local Alignment Search Tool
(BLAST) [24] and GenBank. DGGE banding patterns
were analysed to estimate bacterial diversity for each
specimen using GelCompar II version 6.0 (Applied
Maths, Inc., Texas, USA) software package and the nor-
malised banding patterns were further analysed with
Primer6 version 6.1.12 and Permanova+ addition version
1.02 (PRIMER-E Ltd, Plymouth, UK)[25].
Quantitative real-time PCRs (QPCR) were performed
in reaction volumes of 20 μl containing 1X IQ™ SYBR®
Green Supermix (Bio-Rad Laboratories, Hercules, CA)
and 0.2 mg/ml BSA using a Chromo-4 thermocycler
(Bio-Rad Laboratories, Hercules, CA). Results were ana-
lysed with the Opticon Monitor 3 software (ver. 3.1)
(Bio-Rad Laboratories, Hercules, CA). All assays were
performed in duplicates with primer pair specific ther-
mocycler programs followed by melt curve analysis to
assure specificity of primers. The program for detection
of the total bacterial population [26] consisted of an
initial 4 min, 95°C hot start followed by 35 cycles of 95°
C for 20 s, 60°C for 20 s and 72°C for 45 s with fluores-
cent acquisition after each cycle. The Lactobacillus
[27,28] and the Bifidobacterium[29] group was detected
using the following parameters, 95°C hot start for 4 min
then 35 cycles of 95°C for 20 s, 58°C for 20 s, 72°C for
30 s and 80°C for 30 s followed by acquisition. The
Clostridium coccoides spp. [30] and Bacteroides fragilis
[31] assays had identical parameters, 95°C hot start for 4
min then 35 cycles of 95°C for 20 s, 58°C for 20 s and
72°C for 30 s followed by acquisition. The PCR para-
meters for the detection of Escherichia coli[32] were as
follows: 94°C hot start for 4 min followed by 35 cycles
of 94°C for 30 s, 20 s at 60°C and 45 s at 72°C with
fluorescent acquisition after each cycle.
Statistical analysis
Our analytical approach centred on the practical/clinical
significance of probiotic supplementation rather than
statistical significance alone. We made inferences about
the true (large-sample) effect of the supplement on a
given symptom based on the uncertainty in the effect in
relation to the smallest clinically important values
[33,34]. A full description of the approach utilized is
available in additional file 1.
Descriptive statistics of all measures are presented as
mean ± standard deviation. The effects of supplementa-
tion on illness symptoms were more precise for the
post-only analysis (rather than traditional pre-post ana-
lysis) and are reported here. All symptoms were ana-
lysed per 100 days and a proportion of each subject’s
symptom scores in the shoulder periods was assigned to
the subject’s accumulated scores to account for the start
of supplementation and the monitoring period following
the end of supplementation. The number of symptom
episodes of a given symptom per 100 days, total number
of days of the symptom per 100 days, and total load of
the symptom per 100 days (sum of the product of symp-
tom severity and number of days of the symptom per
100 days) were analysed as ratios: the mean of the pro-
biotic group divided by the mean of the placebo group
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during treatment. Ratios of 1.20 and 1/1.20 ( = 0.83)
were chosen as smallest clinically important differences.
Effects on symptom severity and on all training-related
measures were analysed as differences rather than ratios
of means. Pre-specified sub-group analysis included
examining the data by gender, age and training load.
The smallest important effects for these measures were
derived by standardisation: 0.20 of the pooled between-
subject standard deviation in the control group and pro-
biotic groups [35]. Differences between group means of
subject characteristics were assessed with a modification
[33] of Cohen’s scale [35] for standardised effects (small,
0.20-0.60; moderate, 0.60-1.20; large, > 1.20). Confidence
limits for the effects on symptom scores and training
measures were obtained with bootstrapping. These ana-
lyses were performed with the Statistical Analysis Sys-
tem (Version 9.1, SAS Institute, Cary, NC).
Effects of the probiotic on measures of immunology
and enteric microflora (Q-PCR data) are presented for
pre-post analyses. These measures were log-transformed
before analysis to permit the effect of the treatment to
be properly analyzed as factors or percents, and magni-
tudes of effects were determined by standardisation of
the log-transformed variable. We used the t statistic for
independent samples with unequal variances. Baseline
values of the dependent variable were included as a cov-
ariate in these analyses to account for regression to the
mean. We also investigated the extent to which bacterial
counts accounted for symptom scores in this subsample
of subjects. In these analyses the log-transformed bacter-
ial count or the pre-post change in the log-transformed
count was the covariate, and the dependent variable was
rank-transformed.
A sample size of 80 subjects was required for identify-
ing substantial changes in the incidence of illness [20].
We assumed a rate of upper respiratory tract illness
symptoms of 60% in the placebo group, with sufficient
power (86% at an alpha-level of 0.05) to detect a 50%
reduction in symptoms.
Results
Subjects
A total of 99 subjects were initially allocated to treat-
ment groups but only 88 completed the 11 weeks of
supplementation. One subject dropped out after moving
interstate while the remaining subjects did not complete
the self reported training data and were subsequently
excluded from analysis. There were no substantial differ-
ences between the treatment groups in the time spent
training per week, the number of exercise sessions per
week, session intensity or mean weekly training load or
dietary intake. Subjects were physically and physiologi-
cally similar (Table 1). Dietary intakes were considered
low for an athletic population but not abnormal [36].
Body mass of the athletes did not change substantially
over the course of the study (data not shown).
Table 1 Physical and physiological characteristics of the subjects
Probiotic Placebo Qualitative
difference
Males
N 29 33
Age (y) 35.2 ± 10.3 36.4 ± 8.9 Trivial
Mass (kg) 77.9 ± 8.4 76.9 ± 8.2 Trivial
VO2max (ml/kg/min) 56.5 ± 6.2 55.8 ± 5.6 Trivial
RBC (×1012/L) 5.0 ± 0.3 5.1 ± 0.4 Small
WBC (×1012/L) 6.2 ± 1.7 6.3 ± 1.6 Trivial
Energy intake (kJ) 8954 ± 2870 9138 ± 3168 Trivial
Fibre (g) 16.4 ± 6.9 19.3 ± 11.8 Trivial
Lactobacillus CFU/g 1.4 × 1004 ± 2.5 × 1004 3.8 × 1006 ± 1.3 × 1007 Large
Females
N 18 17
Age (y) 36.5 ± 8.6 35.6 ± 10.2 Trivial
Mass (kg) 57.6 ± 6.1 61.3 ± 9.9 Small
VO2max (ml/kg/min) 53.0 ± 5.0 51.6 ± 7.4 Small
RBC (×1012/L) 4.7 ± 0.2 4.7 ± 0.3 Trivial
WBC (×1012/L) 5.2 ± 1.0 7.6 ± 1.7 Large
Energy intake (kJ) 7491 ± 1336 8133 ± 2512 Trivial
Fibre (g) 15.5 ± 5.1 18.6 ± 14.1 Trivial
Lactobacillus CFU/g 1.4 × 1004 ± 9.4 × 1004 1.8 × 1004 ± 1.7 × 1004 Trivial
VO2max, maximal oxygen uptake; RBC, Data are mean ± SD. red blood cells; WBC, white blood cells; CFU, colony forming units
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Supplementation with L. fermentum (PCC®) had no sub-
stantial effect on the training patterns or performance in
post-testing VO2 max testing of athletes in the experi-
mental group over the duration of the treatment period
(data not shown). The consort checklist can be found in
additional file 1.
Symptoms of illness
The patterns of self-reported gastrointestinal illness
symptoms in probiotic and placebo groups over the
treatment period are shown in Table 2. For male and
female subjects taking L. fermentum (PCC®) there was a
two-fold increase in the number and duration of mild
(low-grade) self-reported gastrointestinal symptoms. No
substantial effect of supplementation was evident
between the groups in moderate and severe GI symp-
toms. However, the self-reported severity score for GI
illnesses at the mean training load in males on the pro-
biotic was 0.7 (0.2 to 1.2) of a scale step lower than for
males on the placebo, and this positive effect of the pro-
biotic increased with higher training loads. The effects
of probiotic supplementation on URT illness load were
unclear in males (0.66; 0.23 to 1.78, mean, 99% confi-
dence intervals) and females (0.99; 0.23 to 3.37). Effects
of supplementation on other measures of URTI were
also unclear. In male subjects, self-reported symptoms
of lower respiratory illness (i.e. number, duration and
severity) were ~50% lower in the probiotic group (Table
3). In contrast, we observed a two-fold increase in the
number and duration, but a reduced severity, of self-
reported symptoms of lower respiratory illness of symp-
toms in females taking L. fermentum (PCC®). The
effects of probiotics on measures of medication usage
(Table 4) generally mirrored the effects on lower
respiratory illness. Covariate analysis in the sub-sample
that provided a faecal sample did not reveal clear trends
between patterns of illness symptoms and supplement-
induced changes in gut bacteria.
Systemic immunity
Table 5 shows that supplementing with L. fermentum
(PCC®) attenuated acute exercise-induced changes in
both anti- and pro-inflammatory cytokines (IL-1RA, IL-6,
IL-8, IL-10, GM-CSF, IFN-g, TNF-a) in males and
females adjusted for mean training load. There were ~20-
75% smaller perturbations in anti-inflammatory and pro-
inflammatory cytokines in males and females taking the
probiotic following supplementation. There were no
substantial differences between the treatment groups in
resting cytokine concentrations from pre- to post-supple-
mentation. We failed to identify substantial relationships
between the reduced exercise-induced perturbations in
cytokines and illness symptoms after supplementation.
The full data on the cytokine concentrations can be
Table 2 The effect of probiotic treatment on the number, duration, severity and combined load of gastrointestinal
symptoms
Effect of probiotic
treatment relative to
placebo
(mean; 99% CI)
Probiotic
group
(mean ± SD)
Placebo
group
(mean ± SD)
Ratio Difference Qualitative
inference
Males
Number of episodes 1.01 ± 1.70 0.49 ± 0.90 2.06;
0.51 to 11
Likely ↑
Duration (d) 3.3 ± 5.8 1.3 ± 7.7 2.57:
0.53 to 17
Likely ↑
Severity (1-3 scale) 1.31 ± 0.33 1.78 ± 0.73 -0.47;
-1.21 to 0.28
Possible ↓
Symptom Load
(severity-days)
4.4 ± 8.1 2.5 ± 5.8 1.76;
0.34 to 15
Possible ↑
Females
Number of episodes 1.44 ± 1.71 0.48 ± 0.71 3.02;
0.76 to 17
Likely ↑
Duration (d) 3.9 ± 5.4 2.1 ± 4.3 1.85;
0.35 to 27
Possible ↑
Severity (1-3 scale) 1.44 ± 0.68 1.75 ± 0.88 -0.31;
-1.39 to 0.79
Possible ↓
Symptom Load
(severity-days)
5.2 ± 7.08 2.9 ± 5.1 1.81;
0.37 to 24
Possible ↑
SD, standard deviation; CI, confidence interval.
Smallest clinically important values for assessing effects qualitatively: ratios, ×/÷1.20; differences, ± 0.5.
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Table 4 The effect of probiotic treatment on the number of, duration of use, severity and combined load of
medications usage
Effect of probiotic
relative to placebo
(mean; 99% CI)
Probiotic
group
(mean ± SD)
Placebo
group
(mean ± SD)
Ratio Difference Qualitative
inference
Males
Number of medication episodes 0.37 ± 0.72 1.26 ± 1.90 0.29;
0.04 to 0.89
Very likely ↓
Total days of medications 5.0 ± 20.8 7.2 ± 14.8 0.70;
0.01 to 2.3
Unclear
Mean # of medications per episode 1.14 ± 0.24 1.29 ± 0.44 -0.15;
-0.57 to 0.24
Possibly trivial
Total # of medications 5.2 ± 20.8 9.1 ± 17.3 0.57;
0.01 to 3.1
Unclear
Females
Number of medication episodes 1.98 ± 2.63 1.08 ± 1.32 1.83;
0.38 to 6.5
Possible ↑
Total days of medications 10.7 ± 18.2 5.8 ± 7.9 1.86;
0.31 to 8.5
Likely ↑
Mean # of medications per episode 1.15 ± 0.24 1.53 ± 0.99 -0.39;
-1.32 to 0.24
Possible ↓
Total # of medications 12.7 ± 20.9 7.4 ± 10.4 1.70;
0.27 to 7.8
Possible ↑
SD, standard deviation; CI, confidence interval.
Smallest clinically important values for assessing effects qualitatively: ratios, ×/÷1.20; differences, ± 0.5.
Table 3 The effect of probiotic treatment on the number, duration, severity and combined load of lower respiratory
symptoms
Effect of probiotic
relative to placebo
(mean; 99% CI)
Probiotic
group
(mean ± SD)
Placebo
group
(mean ± SD)
Ratio Difference Qualitative
inference
Males
Number of episodes 0.6 ± 0.9 1.0 ± 1.5 0.55;
0.15 to 1.60
Likely ↓
Duration (d) 3.5 ± 6.6 7.4 ± 10.3 0.47;
0.10 to 1.43
Likely ↓
Severity (1-3 scale) 1.23 ± 0.36 1.65 ± 0.57 -0.43
-0.92 to 0.08
Possible ↓
Symptom Load
(severity-days)
4.0 ± 7.2 13.0 ± 19.0 0.31;
0.07 to 0.96
Very likely ↓
Females
Number of episodes 1.6 ± 2.1 0.5 ± 0.8 3.27;
0.82 to 21
Likely ↑
Duration (d) 12.2 ± 14.8 5.1 ± 14.7 2.39;
0.45 to 43
Likely ↑
Severity (1-3 scale) 1.38 ± 0.45 2.07 ± 0.77 -0.69
-1.57 to 0.10
Possible ↓
Symptom Load
(severity-days)
17.1 ± 19.0 7.9 ± 20.7 2.18;
0.41 to 27.23
Likely ↑
SD, standard deviation; CI, confidence interval.
Smallest clinically important values for assessing effects qualitatively: ratios, ×/÷1.20; differences, ± 0.5.
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found in the additional files (Additional file 1, Tables S1
to S4).
Mucosal immunity
There were no substantial differences in the concentra-
tion of the mucosal immune measures lactoferrin, lyso-
zyme or SIgA between the probiotic and placebo groups
from pre- to post-supplementation (data not shown).
The concentrations of all proteins in saliva were charac-
terised by large within- and between-subject variability
(coefficients of variation ~200-400%). Further data can
be found in additional file 1, Tables S5 to S6.
Faecal microbiology
Q-PCR analysis revealed a moderate 330% increase (90%
confidence limits; 50% to 1170%) in males in the probio-
tic group and a small 44% decrease (-76 to 27%) in
males in the placebo group in total Lactobacillus num-
bers from pre to post supplementation. Taken together
these changes underpinned a 7.7-fold difference (2.1-
fold to 28-fold) in total Lactobacillus numbers between
the groups. There were trivial differences in total Lacto-
bacillus numbers between females, with those supple-
menting with the probiotic having a 6-fold (0.7-fold to
47-fold) increase and those in the placebo group having
a 3-fold (1.3-fold to 6-fold). There were no substantial
differences in the abundance of E.coli, C. coccoides, Bifi-
dobacterium and Bacteroides fragilis group between
treatments. Raw bacterial counts are detailed in Table 6.
Discussion
Supplementation with L. fermentum PCC® was asso-
ciated with a reduction of symptoms in clinical indices
of lower respiratory illness, GI symptoms at high train-
ing loads, and cold and flu medication use in well-
trained male cyclists. These outcomes were not evident
in well-trained females, with some evidence of an
increase in symptoms. An increase in mild GI symptoms
most likely reflects an adaptive response of the GI tract
to alteration in the composition of the microflora. The
increased recovery of total Lactobacillus species in
faeces may have underpinned the clinical outcomes.
Collectively these studies indicate that L. fermentum
(PCC®) may be a useful nutritional adjunct for physi-
cally active males in both competitive and recreational
settings.
The favourable clinical findings of this study are con-
sistent with previous work undertaken by our group
Table 5 Effect of probiotics on acute post exercise cytokine response (factor changes)
Probiotic
group
(mean ×/÷ SD)
Placebo
group
(mean ± SD)
Ratio effect of
probiotic treatment
relative to placebo
(mean; 99% CI)
Qualitative
inference
Males
Anti-inflammatory
IL-1ra 0.84 ×/÷ 2.42 1.39 ×/÷ 1.42 0.60; 0.41 to 0.88 Very Likely ↓
IL-10 0.95 ×/÷ 1.69 1.16 ×/÷ 1.44 0.78: 0.61 to 0.99 Possible ↓
Immuno-regulatory
IL-6 0.92 ×/÷ 2.14 1.22 ×/÷ 2.1 0.75; 0.51 to 1.1 Likely ↓
Pro-inflammatory
IL-8 0.80 ×/÷2.46 0.87 ×/÷ 2.02 0.71; 0.60 to 1.25 Unclear
GM-CSF 0.78 ×/÷ 2.66 1.75 ×/÷ 2.20 0.45; 0.28 to 0.72 Very Likely ↓
IFN-g 1.2 ×/÷ 2.30 1.49 ×/÷ 2.10 0.81; 0.54 to 1.21 Likely ↓
TNF-a 1.27 ×/÷ 2.02 1.66 ×/÷ 2.22 0.77; 0.51 to 1.14 Likely ↓
Females
Anti-inflammatory
IL-1ra 0.80 ×/÷ 2.44 1.88 ×/÷ 2.16 0.42; 0.23 to 0.78 Very Likely ↓
IL-10 0.89 ×/÷ 1.84 1.45 ×/÷ 2.03 0.61; 0.38 to 1.0 Possible ↓
Immuno-regulatory
IL-6 0.71 ×/÷ 2.93 2.29 ×/÷ 4.8 0.31; 0.11 to 0.84 Likely ↓
Pro-inflammatory
IL-8 0.71 ×/÷ 2.7 1.15 ×/÷ 2.5 0.62; 0.30 to 1.27 Probably ↓
GM-CSF 0.85 ×/÷ 2.75 3.3 ×/÷ 3.9 0.25; 0.10 to 0.64 Very Likely ↓
IFN-g 1.07 ×/÷ 2.8 1.56 ×/÷ 2.1 0.68; 0.47 to 1.0 Likely ↓
TNF-a 1.15 ×/÷ 2.0 1.72 ×/÷ 1.8 0.67 0.47 to 0.94 likely ↓
SD, factor standard deviation; CI, confidence interval.
Smallest clinically important values for assessing effects qualitatively: ratios, × ÷1.20; differences, ± 0.5.
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examining L. fermentum (PCC®) in highly trained run-
ners [12]. A reduction in severity of illness with probio-
tic supplementation should enable individuals to
maintain daily activities and, in the case of athletes,
training and competitive performance. Episodes of ill-
ness often occur during heavy exercise training periods
[6], a time when athletes obtain the greatest improve-
ments in fitness [37]. Illness that interrupts individual
training sessions may prevent athletes from maximising
the effects of their training program. The reduction in
GI symptom intensity at higher training loads has impli-
cations for multi-day events and competitions. These
events are typically characterised by high volume, high
intensity exercise and occasionally an increase in GI
symptoms [38]. The finding that supplementation
reduced symptom severity offers a potential intervention
for these athletes.
The explanation for the higher number and duration
of self-reported symptoms of lower respiratory illness in
females supplementing with the probiotic is unclear and
difficult to reconcile with the reduced severity of symp-
toms. Clinical and immunological differences between
the sexes are well recognised [39]. It is possible that
these divergent clinical findings were an artefact of sam-
pling variation, given the large number of analyses
reported in the study. However, taking the male and
female results together, the findings with the symptoms
are consistent with changes in cold and flu medication
usage. Further work is required to clarify this apparent
discrepancy between the sexes in physiological and clini-
cal responses to probiotic supplementation.
We were unable to identify an effect of probiotic sup-
plementation on URTI in contrast to a previous study
in our laboratory [12]. The effect of the probiotic may
have been more pronounced had there been a higher
rate of illness. The individuals recruited to this study
were well-trained, competitive athletes undertaking daily
exercise. Some individuals undertaking prolonged
intense exercise regularly may suffer a higher rate of ill-
ness than moderately trained individuals [40]. The sub-
jects in this study may not have been as active as the
earlier study, where the elite cyclists and triathletes in
that study typically expended four times more energy on
a daily basis than recreationally active individuals similar
to our subjects.
An increase in mild GI symptoms in individuals taking
the probiotic is consistent with other research examin-
ing probiotic supplementation in healthy individuals
[19]. Mild transient abdominal bloating, flatulence and
cramping have been reported by subjects during the
initial stages of probiotic supplementation [19]. These
symptoms are thought to reflect adaptive changes in the
gastrointestinal tract in response to the introduction of
additional bacterial species, and a subsequent alternation
in fermentation activity. In our study, however, symp-
toms did not abate after the initial 7-10 days and
remained higher in number in the probiotic group
throughout the period of supplementation. The mild GI
symptoms in this study did not affect an individual’s
ability to undertake exercise training and are of little
functional (athletic) consequence. Similar to other clini-
cal probiotic studies [41], we found that despite a higher
number and duration of GI symptoms in those supple-
menting with L. fermentum (PCC®) the severity of
symptoms was lower. This reduction in severity can be
easily explained: the increase in the number and dura-
tion of mild symptoms dilutes the overall symptom
severity.
Table 6 Raw bacterial counts at pre- and post-supplementation
Probiotic group
Pre
(mean ± SD)
Probiotic group
Post
(mean ± SD)
Placebo group
Pre
(mean ± SD)
Placebo group
Post
(mean ± SD)
Males
Total bacteria 2.5 × 1010 ± 1.9 × 1010 2.0 × 1010 ± 9.0 × 109 2.2 ×1010 ± 1.2 × 1010 1.7 × 1010 ± 1.0 × 1010
C. coccoides 1.1 × 1009 ± 1.4 × 1009 8.7 × 1008 ± 1.2 × 1009 1.2 × 1009 ± 1.2 × 1009 8.6 × 1008 ± 6.7 × 1008
E. coli 1.6 × 1005 ± 1.5 × 1005 8.0 × 1005 ± 1.4 × 1006 2.4 × 1005 ± 4.5 × 1005 9.2 × 1005 ± 2.5 × 1006
Bifibacteria 1.7 × 1007 ± 2.4 × 1007 1.4 × 1007 ± 1.6 × 1007 1.0 × 1007 ± 1.8 × 1007 4.4 × 1006 ± 8.8 × 1006
Bacteroides 2.3 × 1006 ± 5.0 × 1006 2.9 × 1006 ± 5.2 × 1006 2.1 × 1006 ± 2.0 × 1006 3.7 × 1006 ± 6.7 × 1006
Lactobacillus 1.4 × 1004 ± 2.5 × 1004 7.2 × 1004 ± 1.3 × 1005 3.8 × 1006 ± 1.3 × 1007 1.0 × 1006 ± 3.5 × 1006
Females
Total bacteria 1.9 × 1010 ± 8.3 × 1010 2.6 × 1010 ± 1.9 × 1010 3.6 × 1010 ± 2.2 × 1010 2.6 × 1010 ± 2.7 × 1010
C.coccoides 1.0 × 1009 ± 1.1 × 1009 1.0 × 1009 ± 8.9 × 1008 2.5 × 1009 ± 2.9 × 1009 9.6 × 1008 ± 8.6 × 1008
E. coli 6.4 × 1006 ± 1.5 × 1007 2.0 × 1007 ± 4.8 × 1007 7.6 × 1003 ± 8.0 × 1003 5.1 × 1004 ± 7.2 × 1004
Bifidobacteria 2.9 × 1006 ± 2.9 × 1006 3.6 × 1006 ± 5.1 × 1006 7.4 × 1006 ± 1.2 × 1007 1.3 × 1006 ± 1.3 × 1006
Bacterioides 1.2 × 1006 ± 1.2 × 1006 2.5 × 1006 ± 3.9 × 1006 5.1 × 1007 ± 9.9 × 1007 6.6 × 1006 ± 9.6 × 1006
Lactobacillus 1.4 × 1004 ± 9.4 × 1004 8.4 × 1004 ± 7.8 × 1004 1.8 × 1004 ± 1.7 × 1004 8.7 × 1004 ± 1.4 × 1005
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The increased susceptibility to illness associated with
exercise may relate to exercise-induced perturbations in
immunity [42], which provide a window of opportunity
for infection. A previous study by our group found that
cytokine responses to controlled exercise differed
between healthy and illness prone athletes, with athletes
prone to URTI showing evidence of impaired inflamma-
tory regulation post-exercise[4]. In the present study,
probiotic consumption reduced the magnitude of the
difference in acute post-exercise cytokine changes
between pre- and post-supplementation in males and
females. Subjects on the placebo exhibited a greater
increase or decrease (across different cytokines) than
those athletes on L. fermentum (PCC®). Cytokine
expression in individuals infected with respiratory
viruses have been proposed as an indicator of disease
severity [43] and blocking inflammatory cytokines
reduces the severity of disease. A substantial 20-60%
reduction in cytokine perturbations associated with pro-
biotic supplementation could represent improved immu-
noregulatory control. While the cytokine control model
remains an attractive explanation for the beneficial
effects of probiotics, the experimental evidence linking
clinical outcomes with nutritional modulation of
immune regulation is lacking.
The increase in total Lactobacillus numbers in males
is presumably the first step in the mechanism linking
supplementation to improved clinical findings in this
group. The sample size of the sub-group was adequate
to demonstrate the effectiveness of the supplement on
gut flora in males. The lack of a substantial difference
in total Lactobacillus numbers between females on the
probiotic and placebo warrants further investigation. In
contrast to males on the placebo, females on the pla-
cebo had an increase in total Lactobacillus numbers in
faeces. Retrospective examination of questionnaires
addressing yoghurt consumption and dietary practices
did not uncover dietary factors to explain the increase.
It may be that females would benefit from higher
doses of probiotics. The microbiota exerts strong
effects on immunity by interacting with a range of
receptors on intestinal epithelial cells, M-cells and den-
dritic cells in the GI tract [44]. The microbiota also
enhances immunity beyond the GI tract through inter-
actions with the common mucosal immune system
(CMIS) [45]. However, covariate analysis of faecal
microbiology and illness symptoms in a subgroup of
participants did not reveal a clear relationship that
would account for the difference in symptoms between
the two groups. This finding is not surprising, given
the limited sample size for the bacterial analysis. A
much larger sample size is required to fully investigate
the role of the microbial flora in mediating the effects
on symptoms of illness.
Conclusion
Supplementation with the probiotic L. fermentum
(PCC®) substantially reduces the severity of self-reported
symptoms and illness load of lower respiratory illness,
use of cold and flu medication, and severity of gastroin-
testinal symptoms at higher training loads, in male ath-
letes. These effects may have been mediated via
reduction in exercise-induced immune perturbations.
The effects on symptoms in females require further
investigation. Increased frequency of mild low-grade
symptoms of GI illness may reflect short-term adaptive
responses in the GI tract with probiotic use. No firm
conclusion can be made about the effects of supplemen-
tation on URTI.
Additional material
Additional file 1: the Additional material file includes the consort
checklist, a more detailed explanation of the analytical approach
and the raw values for the cytokines and salivary protein
concentrations related to tables 2 through to 6.
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